An isocyanate electrolyte solution additive containing a sulfamide structural group has a structure of formula I: ##STR00001##
where R.sub.1 and R.sub.2 are identical or different, R.sub.1 and R.sub.2 are each independently selected from methyl, ethyl, butyl, methoxy, methanesulfonyl, ethanesulfonyl, fluorosulfonyl, trifluoromethanesulfonyl, perfluoroethylsulfonyl, benzenesulfonyl, alkyl-containing benzenesulfonyl, cyano/fluorobenzenesulfonyl and alkoxy-containing benzenesulfonyl, and R.sub.1 and R.sub.2 can be linked to form one of five-membered ring or six-membered ring.

The invention provides novel compounds having the general formula: ##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables R.sup.A, subscript n, ring A, X.sup.2, L, subscript m, X.sup.1, B, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides novel compounds having the general formula: ##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables R.sup.A, subscript n, ring A, X.sup.2, L, subscript m, X.sup.1, B, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment using the compounds are also disclosed.

Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment using the compounds are also disclosed.

The invention provides novel compounds having the general formula:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.A, subscript n, ring A, X.sup.2, L, subscript m, X.sup.1, B, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment using the compounds are also disclosed.

Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment using the compounds are also disclosed.

The present invention provides covalent fluorescent probes for cannabinoid receptor 2 (CB2) having the general formula (I)

##STR00001##

wherein X, n, p, and R.sup.1 to R.sup.4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

The present invention provides covalent fluorescent probes for cannabinoid receptor 2 (CB2) having the general formula (I)

##STR00001##

wherein X, n, p, and R.sup.1 to R.sup.4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.